Supplementary Appendix 6, available at http://onlin elibr ary.wiley. com/doi/10.1002/art.41042/ abstract In adults with AS and IBD, we conditionally recommend treatment with TNFi monoclonal antibodies over treatment with other biologics (PICO 32). This recommendation was based on limited indirect evidence on the risks of flares or new onset of IBD among patients with AS during treatment with biologics, and the much larger literature on the treatment of IBD in general. Patients with AS treated with infliximab or adalimumab have lower risks of IBD exacerbations than those treated with etanercept (see Supplementary Appendix 6, on the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41042/ abstract D. Recommendations for the treatment of patients with either active or stable nonradiographic axial spondyloarthritis Parallel questions on pharmacologic treatment were investigated for patients with nonradiographic axial SpA. There were no relevant